Barclays PLC Sells 137,874 Shares of Tempus AI, Inc. (NASDAQ:TEM)

Barclays PLC cut its stake in Tempus AI, Inc. (NASDAQ:TEM) by 99.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 926 shares of the company’s stock after selling 137,874 shares during the period. Barclays PLC’s holdings in Tempus AI were worth $52,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Federated Hermes Inc. bought a new stake in shares of Tempus AI in the 2nd quarter valued at $19,886,000. Revolution Growth Management Company Inc. acquired a new position in Tempus AI in the second quarter valued at $128,133,000. Allen Operations LLC bought a new stake in Tempus AI during the second quarter valued at $3,831,000. WINTON GROUP Ltd acquired a new stake in Tempus AI during the 2nd quarter worth about $634,000. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of Tempus AI in the 2nd quarter worth about $28,246,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Buying and Selling

In related news, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the sale, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at approximately $38,914,527.62. This represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 865,041 shares of company stock worth $35,917,673 in the last quarter.

Tempus AI Price Performance

Tempus AI stock opened at $37.49 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s fifty day moving average price is $48.59 and its two-hundred day moving average price is $46.96. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Analysts Set New Price Targets

Several equities research analysts recently commented on TEM shares. Guggenheim started coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Loop Capital raised their price target on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.